United States
Choose your country or region:
France
Germany
Italy
Japan
United Kingdom
About
Leadership
Board of Directors
Company History
Corporate Impact and Community Relations
Health Equity
Our Collaborations
Contact Us
Newsroom
News & Stories
Press Releases
Multimedia
Our Tests
Cologuard®
OncoExTra®
Oncoguard® Liver
Oncotype DX®
Oncotype DX Breast DCIS Score®
Oncotype DX Breast Recurrence Score®
Oncotype DX Colon Recurrence Score®
Riskguard™
Provider
Patient
Pipeline & Data
Breast Radiation Score
Next Generation Cologuard
Colorectal Cancer Blood
LBgard® Blood Tubes
Molecular Residual Disease
Cancerguard™
Our Expertise
Cancerguard™ Science
Multi-Cancer Early Detection Thought Leadership
Clinical Studies
Research
Publications & Abstracts
Exact Academy
Investor Relations
Press Releases
Events & Presentations
Environmental, Social, and Governance (ESG)
Stock Information
Financial Information
Email Alerts
Contact Us
Join Our Team
×
DIGITAL NEWSROOM
Posts in:
Exact Sciences News
December 09, 2021
Exact Sciences Commits $500,000 to Urban League Black Business Hub
December 08, 2021
New Data Presented at SABCS
®
2021 Strengthen Value of Oncotype DX Breast Recurrence Score
®
Test to Inform Clinical Decision-making
December 01, 2021
Publication in The New England Journal of Medicine Confirms that Tens of Thousands of Women with Node-positive, Early-stage Breast Cancer Can Avoid Chemotherapy with the Oncotype DX
®
Test
November 23, 2021
New 20-Year Data Published in Urologic Oncology Validates Adverse Pathology as Predictor of Prostate Cancer Outcomes in Clinically Low-Risk Patients
November 18, 2021
Exact Sciences and Jefferson Health Commence Collaboration on Multi-Cancer Earlier Detection
September 14, 2021
Exact Sciences and National Surgical Adjuvant Breast and Bowel Project Announce Clinical Validation Study to Detect Minimal Residual Disease in Colorectal Cancer Patients
May 19, 2021
New Analysis Reinforces Cost-Effectiveness of the Oncotype DX Breast Recurrence Score® Test in Node-Positive Early-Stage Breast Cancer
May 19, 2021
Exact Sciences Strengthens Evidence Supporting Cologuard® and Oncotype DX® Tests and Deep Oncology Pipeline with Multiple Data Presentations at ASCO 2021
May 19, 2021
Exact Sciences Applauds Final Task Force Recommendation That Lowers Starting Age for Colorectal Cancer Screening to 45
January 18, 2017
Cologuard Increases Patient Compliance
August 15, 2016
CMS Affirms Cologuard® Covered Every Three Years for Medicare Advantage Beneficiaries Without Cost Sharing
August 11, 2016
Cologuard® Coverage Expands with Updated Policies from HCSC and Florida Blue
1
2
3
4
5
6
7
8
9
